<DOC>
	<DOCNO>NCT00901550</DOCNO>
	<brief_summary>The purpose study : 1 . To ascertain whether quantitative assessment enhance synovial volume perfusion indices serial Magnetic Resonance Imaging ( MRI ) examination useful indicator responsiveness treatment early Rheumatoid Arthritis ( RA ) use biologic therapy Methotrexate ( MTX ) compare Methotrexate ( MTX ) alone . 2 . To assess cost-effectiveness Tumor Necrosis Factor ( TNF ) blocker compare Methotrexate ( MTX ) monotherapy Rheumatoid Arthritis ( RA ) .</brief_summary>
	<brief_title>The Chinese University Hong Kong Early Arthritis Study</brief_title>
	<detailed_description>This 24-week open-label randomize study . Forty patient randomly assign receive either combination infliximab plus Methotrexate ( MTX ) ( n=20 ) Methotrexate ( MTX ) alone ( n=20 ) All participant receive oral Methotrexate ( MTX ) , start 7.5 mg/week . In patient persistent tender swollen joint , dose escalate graduated manner ( 2.5 mg/week every 1-2 week ) 15 mg/week week 4 20 mg/week week 8 Patients combination group receive infliximab 3mg/kg week 0 , 2 , 6 every 8 week thereafter . Comprehensive assessment make week 0 , 12 , 24 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Men woman , 18 year age old Clinical diagnosis RA duration 24 month ( Fulfilled 1987 American College Rheumatology ( ACR ) criteria RA ) Patients risk develop persistent erosive arthritis DAS 28 ≥ 3.2 Prednisolone &lt; 10mg/day start least 4 week baseline Either ESR ≥ 28 , CRP ≥ 10 , presence rheumatoid factor antiCCP , present HLADRB*0401 DRB1*0404 , radiographic erosion Informed consent Little ability selfcare Previous treatment DMARDs antimalarial Concomitant treatment experimental drug Malignancy within last 5 year Bone marrow hypoplasia Clinically significant renal disease ( serum creatinine level ≥ 150µmol/L ) estimate creatinine clearance &gt; 75ml/min , alanine aminotransferase ( ALT ) exceed upper limit normal History clinically significant adverse reaction murine chimeric proteins History TB last 5 year Known hepatitis B , hepatitis C Had opportunistic infection ( e.g . herpes zoster , cytomegalovirus , Pneumocystis carinii , aspergillosis , histoplasmosis , mycobacteria TB ) within 6 month screen History ongoing chronic recurrent disease ; renal infection , chest infection , urinary tract infection , ulcer skin wound History infect joint prosthesis use antibiotic joint Received intravenous antibiotic within 30 day oral antibiotic within 14 day screen History know demyelinating disease ( multiple sclerosis optic neuritis ) Current sign symptom severe disease ( renal , hepatic , hematologic , endocrine , pulmonary , cardiac , neurologic , etc ) History concurrent CHF History lymphoproliferative disease , splenomegaly Female childbearing potential , unwilling use adequate contraception study Current recent ( within past 3 month ) pregnancy cancer Active smoker , alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>MTX</keyword>
	<keyword>anti-TNF</keyword>
	<keyword>Early RA</keyword>
</DOC>